Illness stability was observed in twenty patients and progressive ailment was observed in 14 individuals. No aim responses were noted. The median survival time was 35 weeks, 5 patients are alive. A complete of 126 cycles have been administered. Grade III IV leukopenia was viewed in 6 cycles. Grade III IV thrombocytopenia was witnessed in five cycles. Grade III anemia was seen in 2 patients. There were no nonhe matologic toxicities and 1 situation of febrile neutropenia. Carboplatin dosing working with the Calvert formula for calculation of region beneath the curve for the therapy of recurrent glioblastoma multiforme is very well tolerated and results in comparable progression cost-free and total survival rates when in contrast with scientific studies utilizing physique surface spot for dosage calculation. Toxicity was purely hematologic and compared favorably with trials making use of body surface place for dosing.
Whilst carboplatin has mild action during the treatment of GBM, the use of this dosing scheme in mixture therapy trials may perhaps allow for enhanced toxicity. TA 23. Major CENTRAL NERVOUS Technique LYMPHOMA WITH OCULAR INVOLVEMENT, AN Worldwide PCNSL COLLABORATIVE GROUP REPORT S. A. Grimm, J. S. Pulido, A. Omuro, J. Y. Blay, A. J. M. Ferreri, N. Doolittle, T. Batchelor, inhibitor mapk inhibitors T. Siegal, K. Jahnke, T. N. Shenkier, A. J. Hall, F. Graus, U. Herrlinger, D. Schiff, J. Raizer, J. Rubenstein, N. Laperiere, and L. E. Abrey, Memorial Sloan Kettering Cancer Center, Ny, NY, USA, Hospital Pitie Salpetriere, Paris, France, International Extranodal Lymphoma Examine Group, Oregon selelck kinase inhibitor Wellness Sciences University, Portland, OR, USA, Massachusetts Basic Hospital, Boston, MA, USA, Hadassah Hebrew University Hospital, Tel Aviv, Israel, Mayo Clinic, Rochester, MN, USA, British Columbia Cancer Agency, Vancouver, Canada, Royal Melbourne Hospital, Melbourne, Australia, Barcelona, Spain, University of Tuebingen, Tuebingen, University of Virginia, Charlottesville, VA, USA, Northwestern, Chicago, IL, USA, UCSF, San Francisco, CA, USA, Princess Margaret Hospital, Toronto, Canada Somewhere around 15% to 25% of PCNSL individuals have ocular involve ment on the time of diagnosis.
Simply because these individuals signify a compact frac tion of individuals having a uncommon condition, the organic background and optimum treat ment of PCNSL with ocular dissemination are unknown. A retrospective study of 225 sufferers with ocular lymphoma

was assembled from 15 centers in 8 countries. All patients had parenchymal brain lymphoma in addition to ocular involvement, none had systemic lymphoma. The median age at diag nosis was 58 years. Fifty seven percent of the individuals had been women. The median ECOG performance status was 2. The median latency period from symptom onset to diagnosis was 3 months.